Compare CDMOs with cytotoxic compound handling and ADC manufacturing capabilities. Filter by containment level, bioconjugation expertise, and regulatory approvals.
48 companies listed
Cytotoxic compound handling covers the manufacturing of drugs designed to kill cells -- primarily cancer chemotherapy agents and ADC payloads. These compounds are inherently hazardous to manufacturing workers and require specialized containment, waste handling, and decontamination procedures that go beyond standard pharmaceutical manufacturing.
ADC manufacturing adds unique requirements: the cytotoxic payload must be synthesized under high containment, then conjugated to a monoclonal antibody under aseptic conditions. This intersection of high-potency chemistry and sterile biologics processing is one of the most demanding manufacturing challenges in pharma. CDMOs with both capabilities under one roof command premium positioning.
India
Aarti Pharmalabs Limited is a leading Indian small-molecule CDMO specializing in API and drug substance development and manufacturing. They operate six manufacturing plants with two R&D centers, accredited by USFDA, EU GMP, EDQM, and KFDA. They provide services from process R&D through stability studies, scale-up, process validation, and commercial manufacturing, including high-potent/cytotoxic molecules and flow chemistry.
Italy
AbbVie Contract Manufacturing is an embedded CMO within AbbVie, providing third-party contract manufacturing services for over 40 years across 12 locations in the US and Europe. They offer services spanning antibody drug conjugates, aseptic fill/finish, biologics (mAbs and derivatives), custom API, eye care, hot melt extrusion, HPAPI, and oral solid dose manufacturing.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.